

## Result Preview



### Company

Alembic Pharma.
Ajanta Pharma
Alkem Lab.
Apollo Hospitals
Aurobindo Pharma
Biocon
Cipla
Dr. Agarwal's Healthcare
Divi's Lab.
Dr. Reddy's Lab.
Eris Lifesciences
Gland Pharma
Glenmark Pharma.
Global Health
Granules India
GSK Pharma
IPCA Lab.
Laurus Labs
Lupin
Mankind Pharma
Max Healthcare
Piramal Pharma
Rubicon Research
Sun Pharma
Torrent Pharma
Zydus Lifesciences

## EBITDA growth trails revenue growth for third straight quarter

### Chronic-led DF growth and capacity expansion to shape sectoral trends

We expect pharma companies to deliver steady growth in aggregate revenue in 3QFY26, supported by improving domestic formulations (DF) momentum. However, increased competition in select products for US market and slower pace of potential launches should keep EBITDA growth trend in check. Aggregate DF sales are projected to grow 8.7% YoY to INR256b, led by continued outperformance of chronic therapies, while acute therapies remain subdued. US generics sales are expected to decline due to competition in select products, namely g-Revlimid. The hospital sector is expected to post 9% YoY revenue growth, even as occupancy declines due to aggressive capacity additions. Average revenue per occupied bed (ARPOB) should improve moderately on a higher chronic specialty mix. Having said this, the front-loading of opex related to newer hospitals/bed additions would keep margins under pressure.

### DF: Expect recovery post GST disruption/steady thrust in chronic therapies Coverage companies to see sequential improvement in growth

For companies under our coverage, we expect aggregate DF segment sales to increase by 8.7% YoY to INR256b in 3QFY26. Sequential improvement in DF is attributed to higher sales after GST transition. However, growth is likely to remain below the double-digit levels seen in earlier quarters due to weak seasonality. That said, our coverage companies are expected to track industry growth, supported by continued product launches and an increasing focus on chronic therapy portfolios.

### Chronic therapies to outperform as acute growth remains subdued

In the first two months of 3QFY26 (Oct/Nov'25), chronic therapies recorded strong growth of 15.5% YoY, significantly outperforming the 11.0%/11.3% YoY growth seen in 1Q/2QFY26. In contrast, acute therapies continued to see muted performance, with growth of 7.0% YoY vs. 7.7%/5.0% YoY in 1Q/2QFY26. Robust traction in cardiac and anti-diabetic therapies supported outperformance vs. IPM during the quarter. However, overall IPM growth was partially constrained by weaker trends in anti-infective, gastro, and pain segments.

### AJP/SUNP to record strong YoY DF sales in 3QFY26

We expect AJP/SUNP to report sales growth of 16.2%/13.2% YoY, driven by price increases, new product launches, and improved productivity from the medical representative (MR) force. AJP is expected to deliver double-digit growth across dermatology, ophthalmology, and pain therapies, based on IQVIA data for the three months ending Nov'25. IPCA is likely to record broad-based growth across therapies, although the anti-infective segment is expected to remain subdued. We expect ERIS to report growth of 15% YoY driven by growth in both branded DF and exports.

### US sales: 3Q to reflect minimal contribution from g-revlimid

#### US sales expected to decline YoY in 3QFY26; excl. DRRD, sales likely to rise

For our coverage universe, US revenue is expected to decline 1.3% YoY to USD2.3b in 3QFY26, driven largely by a sharp 21.5% YoY decline in DRRD's sales to USD310m. Excluding DRRD, US revenue is expected to grow 2.8% YoY. Cipla/ARBP are expected to post 15%/7% YoY decline in US sales due to lower sales of g-Revlimid. **Notably, 3Q would showcase base business performance for DRRD and Cipla in US segment.**

#### LPC/TRP to be outperformers for the quarter

The overall decline would be mitigated by robust growth in LPC/TRP. LPC is likely to deliver strong US growth of 27.6% YoY on account of steady traction in g-Tolvaptan/g-Spiriva/Mirabegron, offset by price erosion in base portfolio and competition in g-Albuterol. Delayed competitor approval of g-Tolvaptan would extend the low-competition window, supporting continued growth.

TRP/ALKEM/ALPM/ZYDUS are expected to grow 25%/8.5%/5%/3.5% YoY in 3QFY26, driven by contributions from new product launches. GNP is likely to report stable US revenue as pricing pressure in base portfolio may constrain growth.

#### Pace of approvals for our coverage companies has slowed down

During the quarter, 12 facilities belonging to our coverage companies were inspected by the USFDA. **At the industry level, final approvals stood at 154 in 3QFY26 (vs. 144 approvals in 2QFY26).** For companies under our coverage, there were 32 final approvals during 3QFY26. The approval trend turned meaningfully weaker after 4QFY25, with approvals declining for three consecutive quarters, indicating consistent moderation in regulatory clearances.

### Hospitals: Capacity-led growth with temporary pressure on operating metrics

For the hospitals under our coverage, revenue is expected to grow 9% YoY to INR95b in 3QFY26, driven by consistent operational execution, strong expansion of bed capacities, along with the development of new facilities, which together have enhanced operating metrics and profitability. For 3Q, we expect EBITDA margins of our coverage companies to be ~19% and aggregate EBITDA to grow 10% YoY.

Overall occupancy is expected to decline by ~480bp YoY, while ARPOB is projected to see a moderate increase, supported by a greater focus on chronic specialties. Hospitals will continue to undertake aggressive capacity expansion through new bed additions and doctor hiring to scale patient volumes and improve occupancy levels. Sector growth has been impacted by the rollout of GST 2.0 and seasonal factors. Near-term margins are expected to stay subdued owing to higher operating costs linked to capacity ramp-up, although profitability and returns should normalize and improve over the medium term as utilization improves.

MAXHEALTH plans to add ~800 beds in FY26 at Nanavati Max, the Saket Complex, and Gomti Nagar through brownfield expansion. APHS plans to operationalize 1,687 beds during 2HFY26-FY27. It has recently commissioned a 250-bed facility in Swargate, Pune. Medanta fully commercialized its 550-bed super-specialty hospital in 3QFY26 and plans to add ~400 beds in Lucknow and Patna by the end of FY27.

We expect APHS to post 11%/20%/23% YoY growth in sales/EBITDA/PAT for 3QFY26. MEDANTA is expected to deliver sales/PAT growth of 13%/7% YoY, while EBITDA may decline 1% YoY. Profitability is likely to remain subdued as operating expenses from the recently commissioned Noida hospital continue to weigh on margins. MAXHEALTH is also likely to deliver subdued performance, with sales/EBITDA posting 4%/2% YoY growth and PAT declining 1% YoY.

#### GNP/LPC/LAURUS to outperform within the healthcare pack


- In 3QFY26, we expect GNP/LPC/LAURUS to deliver 41%/38%/36% YoY growth in EBITDA. For GNP, income from ISB2001 deal and progress on scale-up of DF business after GST-led inventory corrections to drive financial performance.
- Steady approval in US and focus on chronic therapies in DF to support superior show for LPC in 3QFY26. Improvement in product mix and better operational efficiency should drive EBITDA growth for LAURUS in 3QFY26.
- DRRD/CIPLA/PIRPHARM are expected to report a YoY decline of 21%/20%/11% in EBITDA for the quarter. Increased competition, leading to heightened pricing pressure on products including g-Revlimid, along with operational inefficiencies, may weigh on EBITDA performance.
- We have reduced our estimates for PIRPHARM by 13%/9% for FY27/FY28, reflecting our expectation of only a gradual recovery across its segments over the mid-term and the need for greater visibility on order inflows going forward.
- **Our top ideas:** Laurus Labs (CDMO differentiation), Biocon (biosimilar frontrunner), and Rubicon (differentiated US play).

Exhibit 1: Summary of quarterly performance


Sector	CMP		SALES (INR m)			EBITDA (INR M)			NET PROFIT (INR m)		
	(INR)	Reco	Dec-25	Var % YoY	Var % QoQ	Dec-25	Var % YoY	Var % QoQ	Dec-25	Var % YoY	Var % QoQ
Ajanta Pharma	2937	Buy	13,155	14.8	-2.8	3,644	13.6	-1.2	2,594	18.1	-0.7
Alembic Pharma	836	Neutral	18,509	9.3	-3.1	3,035	16.7	-3.8	1,796	29.7	4.7
Alkem Lab	5588	Neutral	36,750	8.9	-8.1	7,093	-6.6	-23.0	5,776	-7.7	-27.9
Apollo Hospitals	7129	Buy	61,260	10.8	-2.8	9,128	19.9	-3.0	4,563	22.6	-4.4
Aurobindo Pharma	1215	Buy	80,651	1.1	-2.7	16,937	4.0	0.9	9,315	5.7	10.2
Biocon	393	Buy	45,447	18.9	5.8	8,953	13.9	7.2	1,580	259.6	73.6
Blue Jet Healthcare	531	Buy	3,284	3.5	98.5	1,168	-5.1	112.6	932	-4.9	78.7
Cipla	1511	Neutral	72,820	3.0	-4.1	15,875	-20.2	-16.2	11,270	-17.4	-16.6
Divis Labs	6390	Neutral	26,788	15.5	-1.3	8,438	13.6	-5.0	6,148	5.8	-4.1
Dr Agarwals Health.	502	Buy	5,169	20.0	3.6	1,339	22.1	-1.7	313	67.3	5.4
Dr Reddy's Labs	1255	Neutral	80,851	-1.8	-8.2	17,221	-20.7	-19.0	11,473	-13.0	-25.6
Eris Lifescience	1531	Neutral	8,366	15.0	5.6	3,045	21.7	5.7	1,268	51.6	5.7
Gland Pharma	1714	Buy	16,065	16.1	8.0	3,807	5.8	21.3	2,347	14.7	27.8
Glenmark Pharma	2066	Buy	37,704	11.3	58.6	8,483	41.3	LP	5,281	51.8	LP
Global Health	1217	Buy	10,684	13.2	-2.8	2,393	-0.8	3.6	1,522	6.5	4.4
Granules India	615	Buy	12,611	10.9	-2.8	2,775	20.5	-0.3	1,403	19.3	7.4
GSK Pharma	2483	Neutral	10,529	10.9	7.4	3,643	28.8	8.5	2,752	24.6	8.0
IPCA Labs.	1404	Buy	24,081	7.2	-5.8	4,840	4.5	-11.2	2,779	12.0	-14.4
Laurus Labs	1107	Buy	16,611	17.4	0.5	3,887	36.3	-3.6	1,618	75.3	-16.6
Laxmi Dental	271	Buy	678	10.0	-6.1	105	9.4	-4.6	75	57.1	-11.6
Lupin	2106	Neutral	67,614	18.8	-4.1	18,999	38.0	-11.1	11,992	40.2	-9.6
Mankind Pharma	2203	Buy	35,711	11.6	-3.4	8,928	9.4	-3.1	5,040	34.9	-0.6
Max Healthcare	1063	Buy	23,658	4.3	-8.0	6,293	2.0	-8.4	3,949	-0.7	-7.2
Piramal Pharma	179	Buy	22,961	4.2	12.3	3,008	-10.9	89.5	315	757.2	LP
Rubicon Research	662	Buy	4,580	NA	11.2	1,008	NA	6.9	627	NA	16.4
Sun Pharma	1729	Buy	1,46,486	12.2	1.7	39,991	11.9	-0.6	30,123	9.0	7.8
Torrent Pharma	3885	Neutral	31,944	13.7	-3.3	10,318	12.9	-4.7	5,865	16.6	-2.4
Zydus Lifesciences	917	Neutral	63,704	20.9	4.0	15,799	21.5	-1.4	9,675	1.9	-4.7
<b>Healthcare</b>			<b>9,78,672</b>	<b>10.4</b>	<b>0.0</b>	<b>2,30,153</b>	<b>8.0</b>	<b>2.7</b>	<b>1,42,392</b>	<b>9.8</b>	<b>6.5</b>

Source: Company, MOFSL

**Exhibit 2: Relative performance – three months (%)**




**Exhibit 3: Relative performance – one year (%)**




Source: Bloomberg, MOFSL

**Exhibit 4: DF sales to grow 8.7% YoY in 3QFY26**




Note: Growth is ex-Mankind, Source: MOFSL, Company

**Exhibit 5: US sales to decline 1.3% YoY in 3QFY26**




Source: MOFSL, Company

**Exhibit 6: 154 approvals in 3Q on an industry-wide basis**




Source: MOFSL, Company

**Exhibit 7: 32 ANDAs approved on an aggregate basis for our coverage universe in 3QFY26**




Source: MOFSL, Company

**Exhibit 8: Expect sales to grow 10% YoY in 3QFY26**




Source: MOFSL, Company

**Exhibit 9: EBITDA to grow 7% YoY**



Source: MOFSL, Company

**Exhibit 10: PAT to grow 8.7% YoY**



Source: MOFSL, Company

**Exhibit 11: The USFDA inspection history of our coverage companies for the quarter**

Company	Inspection Date	Inspection Facility	Outcome	Observations
Biocon	Oct-25	Cranbury, New Jersey	EIR	VAI
	Nov-25	API Facility (Site 6), Visakhapatnam	Form 483	2
Aurobindo Pharma	Dec-25	Unit V, Apitoria, Sangareddy	Form 483	3
	Dec-25	Unit IV, APL Healthcare, SPSR Nellore	Form 483	5
Dr Reddy	Nov-25	API Facility, Srikakulam	Form 483	0
	Dec-25	Formulations Facility, Srikakulam	Form 483	5
Lupin	Nov-25	Nagpur Unit-1	Form 483	0
	Nov-25	Bioresearch Centre, Pune	Form 483	0
Zydus	Nov-25	Goa	Form 483	7
	Nov-25	SEZ I, Ahmedabad	Form 483	2
IPCA	Dec-25	Tarapur, Palghar	Form 483	3
Glenmark Pharma	Nov-25	Formulations Facility, Chhatrapati Sambhajanagar	Form 483	0

Source: MOFSL, Company

**Exhibit 12: Comparative valuation**

Company Name	CMP (INR)	Reco	EPS (INR)			PE (x)			PB (x)			ROE (%)		
			FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
<b>Healthcare</b>						<b>35.9</b>	<b>30.7</b>	<b>26.8</b>	<b>4.9</b>	<b>4.3</b>	<b>3.8</b>	<b>13.7</b>	<b>14.1</b>	<b>14.2</b>
Ajanta Pharma	2,937	Buy	83.0	99.7	111.7	35.4	29.5	26.3	8.0	6.7	5.6	24.9	24.8	23.2
Alembic Pharma	836	Neutral	36.2	44.9	53.7	23.1	18.6	15.6	2.8	2.5	2.2	12.8	14.2	14.9
Alkem Lab	5,588	Neutral	197.0	185.8	207.3	28.4	30.1	27.0	4.9	4.4	4.0	18.4	15.5	15.6
Apollo Hospitals	7,129	Buy	130.8	155.6	193.1	54.5	45.8	36.9	9.9	8.2	6.7	20.6	20.2	20.5
Aurobindo Pharma	1,215	Buy	61.9	77.7	90.6	19.6	15.6	13.4	2.0	1.8	1.6	10.5	11.8	12.3
Biocon	393	Buy	3.0	7.1	9.4	132.8	55.5	41.9	2.1	2.0	1.9	2.2	5.1	6.4
Blue Jet Healthcare	531	Buy	19.7	23.3	28.5	26.9	22.8	18.6	6.3	5.0	4.0	26.5	24.6	24.0
Cipla	1,511	Neutral	61.2	61.7	68.6	24.7	24.5	22.0	3.4	3.0	2.7	13.8	12.4	12.2
Divis Labs	6,390	Neutral	91.1	114.9	137.0	70.1	55.6	46.6	10.1	9.0	7.9	15.3	17.2	18.1
Dr Agarwals Health.	502	Buy	4.0	5.2	7.9	125.8	96.0	63.8	7.9	7.3	6.6	6.5	7.9	10.8
Dr Reddy's Labs	1,255	Neutral	65.7	62.6	67.3	19.1	20.1	18.7	2.7	2.4	2.1	15.1	12.7	12.2
Eris Lifescience	1,531	Neutral	36.0	50.8	61.1	42.6	30.1	25.1	6.4	5.4	4.5	16.1	19.5	19.6
Gland Pharma	1,714	Buy	54.2	68.0	80.4	31.6	25.2	21.3	2.8	2.5	2.3	9.3	10.6	11.2
Glenmark Pharma	2,066	Buy	19.1	77.5	87.4	108.1	26.7	23.6	6.3	5.1	4.3	5.9	21.2	19.7
Global Health	1,217	Buy	22.3	29.5	35.4	54.7	41.3	34.3	8.4	7.2	6.1	16.4	18.8	19.3
Granules India	615	Buy	23.5	31.2	38.1	26.2	19.7	16.2	3.5	3.0	2.5	14.3	16.4	17.1
GSK Pharma	2,483	Neutral	61.3	70.6	79.8	40.5	35.2	31.1	16.7	12.9	10.2	41.2	36.8	32.7
IPCA Labs.	1,404	Buy	42.8	52.0	61.6	32.8	27.0	22.8	4.5	4.0	3.5	14.7	15.7	16.2
Laurus Labs	1,107	Buy	13.4	16.8	19.6	82.4	65.9	56.4	11.4	10.0	8.7	14.7	16.2	16.5
Laxmi Dental	271	Buy	7.5	10.9	13.2	35.9	24.8	20.6	6.0	4.8	3.9	18.1	21.4	20.9
Lupin	2,106	Neutral	102.9	100.1	102.6	20.5	21.0	20.5	4.2	3.5	3.0	23.4	18.3	15.9
Mankind Pharma	2,203	Buy	45.6	59.3	72.1	48.3	37.1	30.6	5.8	5.1	4.5	12.5	14.6	15.8
Max Healthcare	1,063	Buy	16.9	23.4	25.5	63.0	45.4	41.6	8.5	7.3	6.2	14.5	17.3	16.1
Piramal Pharma	179	Buy	-0.5	1.3	3.2	-330.6	142.3	55.3	2.6	2.6	2.5	-0.9	2.0	5.1
Rubicon Research	662	Buy	13.6	18.3	24.6	48.6	36.1	27.0	9.0	7.4	5.9	25.6	22.5	24.4
Sun Pharma	1,729	Buy	49.2	57.5	64.7	35.1	30.1	26.7	5.1	4.5	4.0	15.4	16.0	15.8
Torrent Pharma	3,885	Neutral	69.4	83.8	103.2	55.9	46.3	37.6	7.2	6.0	5.0	28.2	28.4	29.1
Zydus Lifesciences	917	Neutral	44.6	44.7	48.9	20.5	20.5	18.8	3.2	2.8	2.5	17.1	14.8	14.2



The tables below provide a snapshot of actual and estimated numbers for companies under the MOFSL coverage universe. Highlighted columns indicate the quarter/financial year under review.

## Ajanta Pharma

Buy

**CMP: INR2,937 | TP: INR3,400 (16%)**
**EPS CHANGE (%): FY26|27|28: 0|0|0**

- Expect DF sales to grow 14% YoY to INR4b, due to superior show in derma/anti-diabetic/ophthal.
- US growth momentum to sustain in 3QFY26, with 26% YoY growth driven by new launches and market share gains.
- Postponement of supplies across Asian geographies is projected to revive growth in 3QFY26 to some extent.
- Growth momentum in Africa to sustain with 18.6% YoY growth led by superior execution and partly on low base.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Net Sales</b>	<b>11,449</b>	<b>11,866</b>	<b>11,461</b>	<b>11,704</b>	<b>13,027</b>	<b>13,537</b>	<b>13,155</b>	<b>13,012</b>	<b>46,481</b>	<b>52,731</b>
YoY Change (%)	12.1	15.4	3.7	11.0	13.8	14.1	14.8	11.2	10.4	13.4
Total Expenditure	7,846	8,498	8,253	8,733	9,262	9,850	9,511	9,434	33,330	38,056
<b>EBITDA</b>	<b>3,604</b>	<b>3,368</b>	<b>3,208</b>	<b>2,972</b>	<b>3,765</b>	<b>3,688</b>	<b>3,644</b>	<b>3,578</b>	<b>13,152</b>	<b>14,675</b>
YoY Change (%)	28.1	15.9	-0.3	6.8	4.5	9.5	13.6	20.4	12.2	11.6
Margins (%)	31.5	28.4	28.0	25.4	28.9	27.2	27.7	27.5	28.3	27.8
Depreciation	340	344	360	398	413	430	375	371	1,441	1,588
<b>EBIT</b>	<b>3,264</b>	<b>3,024</b>	<b>2,849</b>	<b>2,574</b>	<b>3,352</b>	<b>3,258</b>	<b>3,269</b>	<b>3,208</b>	<b>11,710</b>	<b>13,087</b>
YoY Change (%)	31.5	17.7	-0.9	5.4	2.7	7.7	14.8	24.6	13.0	11.8
Interest	7	60	79	61	53	34	66	66	207	218
Other Income	182	195	129	111	170	197	165	175	616	706
<b>PBT before EO expense</b>	<b>3,439</b>	<b>3,159</b>	<b>2,898</b>	<b>2,624</b>	<b>3,469</b>	<b>3,421</b>	<b>3,368</b>	<b>3,316</b>	<b>12,119</b>	<b>13,575</b>
Extra-Ord expense	-217	-257	176	71	-158	-13	0	0	-227	-171
<b>PBT</b>	<b>3,221</b>	<b>2,902</b>	<b>3,074</b>	<b>2,694</b>	<b>3,311</b>	<b>3,408</b>	<b>3,368</b>	<b>3,316</b>	<b>11,892</b>	<b>13,404</b>
Tax	764	738	745	442	758	806	775	789	2,688	3,128
Effective Rate (%)	23.7	25.4	24.2	16.4	22.9	23.7	23.0	23.8	22.6	23.3
<b>Reported PAT</b>	<b>2,458</b>	<b>2,165</b>	<b>2,329</b>	<b>2,253</b>	<b>2,553</b>	<b>2,602</b>	<b>2,594</b>	<b>2,527</b>	<b>9,204</b>	<b>10,276</b>
<b>Adj PAT</b>	<b>2,624</b>	<b>2,356</b>	<b>2,196</b>	<b>2,194</b>	<b>2,675</b>	<b>2,612</b>	<b>2,594</b>	<b>2,527</b>	<b>9,369</b>	<b>10,407</b>
YoY Change (%)	30.8	26.5	3.3	16.4	2.0	10.9	18.1	15.2	18.9	11.1
Margins (%)	22.6	19.5	18.9	18.6	20.3	19.0	19.5	19.2	19.9	19.5

## Alembic Pharma

Neutral

**CMP: INR848 | TP: INR882 (6%)**
**EPS CHANGE (%): FY26|27|28: 2|1.9|3**

- New launches to drive 9% YoY growth in US sales, reaching USD66m during the quarter.
- EBITDA margins expected to improve to 16.4% driven by better operating leverage.
- Expect DF sales to grow modestly by 4.3% YoY in 3Q, impacted by muted show in anti-infective, respiratory and gastro therapies.
- Expect 12% YoY growth in the API business, led by lower base and improved demand.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Net Sales</b>	<b>15,617</b>	<b>16,480</b>	<b>16,927</b>	<b>17,696</b>	<b>17,107</b>	<b>19,102</b>	<b>18,509</b>	<b>18,870</b>	<b>66,721</b>	<b>73,588</b>
YoY Change (%)	5.1	3.3	3.8	16.7	9.5	15.9	9.3	6.6	7.1	10.3
Total Expenditure	13,249	14,087	14,325	14,977	14,294	15,945	15,474	15,757	56,639	61,469
<b>EBITDA</b>	<b>2,368</b>	<b>2,393</b>	<b>2,602</b>	<b>2,719</b>	<b>2,813</b>	<b>3,157</b>	<b>3,035</b>	<b>3,114</b>	<b>10,082</b>	<b>12,119</b>
YoY Change (%)	19.2	14.9	-2.4	4.6	18.8	31.9	16.7	14.5	8.1	20.2
Margins (%)	15.2	14.5	15.4	15.4	16.4	16.5	16.4	16.5	15.1	16.5
Depreciation	690	705	700	690	738	761	798	813	2,786	3,109
<b>EBIT</b>	<b>1,678</b>	<b>1,688</b>	<b>1,902</b>	<b>2,029</b>	<b>2,075</b>	<b>2,396</b>	<b>2,238</b>	<b>2,300</b>	<b>7,297</b>	<b>9,010</b>
YoY Change (%)	26.6	19.9	-3.6	6.5	23.7	42.0	17.7	13.3	10.5	23.5
Interest	132	188	223	245	235	242	205	159	788	841
Other Income	21	167	95	142	65	69	171	375	425	680
<b>PBT</b>	<b>1,567</b>	<b>1,796</b>	<b>1,774</b>	<b>1,926</b>	<b>1,905</b>	<b>2,223</b>	<b>2,204</b>	<b>2,516</b>	<b>7,063</b>	<b>8,848</b>
Rate (%)	14.4	15.2	22.6	18.3	19.1	23.9	18.1	18.0	17.7	19.8
MI & P/L of Asso. Cos.	-5	-11	-11	4	-3	-24	9	11	-23	-7
<b>Reported PAT</b>	<b>1,347</b>	<b>1,534</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,715</b>	<b>1,796</b>	<b>2,052</b>	<b>5,834</b>	<b>7,107</b>
<b>Adj PAT</b>	<b>1,347</b>	<b>1,425</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,715</b>	<b>1,796</b>	<b>2,052</b>	<b>5,725</b>	<b>7,107</b>
YoY Change (%)	11.6	3.6	-23.5	-12.3	14.6	20.4	29.7	30.8	-7.2	24.1
Margins (%)	8.6	8.6	8.2	8.9	9.0	9.0	9.7	10.9	8.6	9.7

## Alkem Labs

**Neutral**

**CMP: INR5,588 | TP: INR5,500 (-2%)**

**EPS CHANGE (%): FY26|27|28: (6.7)|(1)|(1)**

- Expect DF sales to grow 8% YoY, impacted by weakness in Anti-infectives.
- Expect US sales to grow by 14% YoY to INR7.2b, backed by new product launches.
- Expect opex related to Enzene US plant/med tech to affect profitability for 3Q.
- Ex-US sales to grow at 22% YoY on the back of superior execution in Australia and other European markets.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Net Revenues</b>	<b>30,318</b>	<b>34,147</b>	<b>33,743</b>	<b>31,438</b>	<b>33,711</b>	<b>40,010</b>	<b>36,750</b>	<b>34,116</b>	<b>129,645</b>	<b>144,127</b>
YoY Change (%)	2.2	-0.7	1.5	7.1	11.2	17.2	8.9	8.5	2.3	11.2
Total Expenditure	24,232	26,618	26,149	27,525	26,321	30,802	29,658	29,340	104,524	73,705
<b>EBITDA</b>	<b>6,086</b>	<b>7,528</b>	<b>7,594</b>	<b>3,913</b>	<b>7,391</b>	<b>9,208</b>	<b>7,093</b>	<b>4,776</b>	<b>25,121</b>	<b>28,007</b>
YoY Change (%)	56.4	0.8	7.3	-2.7	21.4	22.3	-6.6	22.1	11.9	11.5
Margins (%)	20.1	22.0	22.5	12.4	21.9	23.0	19.3	14.0	19.4	19.4
Depreciation	805	789	853	1,125	877	936	955	928	3,572	3,696
<b>EBIT</b>	<b>5,282</b>	<b>6,739</b>	<b>6,741</b>	<b>2,788</b>	<b>6,514</b>	<b>8,272</b>	<b>6,138</b>	<b>3,848</b>	<b>21,550</b>	<b>24,311</b>
YoY Change (%)	66.7	0.2	5.7	-12.5	23.3	22.7	-8.9	38.0	57.4	24.9
Margins (%)	17.4	19.7	20.0	8.9	19.3	20.7	16.7	11.3	16.6	16.9
Interest	291	281	360	284	298	350	310	320	1,217	1,278
Other Income	1,203	1,345	930	1,460	1,365	1,400	1,150	1,050	4,937	4,965
<b>PBT after EO Exp</b>	<b>6,194</b>	<b>7,803</b>	<b>7,311</b>	<b>3,963</b>	<b>7,710</b>	<b>9,321</b>	<b>6,978</b>	<b>4,578</b>	<b>25,270</b>	<b>28,127</b>
Tax	691	783	903	733	1,027	1,162	1,012	687	3,110	3,888
Rate (%)	11.2	10.0	12.3	18.5	13.3	12.5	14.5	15.0	12.3	13.9
<b>PAT (pre Minority Interest)</b>	<b>5,502</b>	<b>7,020</b>	<b>6,408</b>	<b>3,230</b>	<b>6,683</b>	<b>8,159</b>	<b>5,966</b>	<b>3,891</b>	<b>22,160</b>	<b>24,240</b>
Minority Interest	51	133	150	172	41	145	190	195	505	571
<b>Reported PAT</b>	<b>5,452</b>	<b>6,886</b>	<b>6,258</b>	<b>3,059</b>	<b>6,643</b>	<b>8,014</b>	<b>5,776</b>	<b>3,696</b>	<b>21,655</b>	<b>23,669</b>
<b>Adj Net Profit</b>	<b>5,452</b>	<b>6,886</b>	<b>6,258</b>	<b>3,059</b>	<b>6,531</b>	<b>8,014</b>	<b>5,776</b>	<b>3,696</b>	<b>21,655</b>	<b>24,017</b>
YoY Change (%)	90.1	2.0	-2.6	0.6	19.8	16.4	-7.7	20.8	13.5	10.9

## Apollo Hospitals

**Buy**

**CMP: INR7,129 | TP: INR9,015 (26%)**

**EPS CHANGE (%): FY26|27|28: 0.5|0|0**

- Sales/EBITDA are likely to grow 11%/16% YoY to INR61b/INR8.8b, supported by steady growth across segments.
- Progress on new projects in hospital segment.
- Progress on comprehensive franchise build-up of healthco comprising online/offline pharmacy and back-end integration
- Outlook on GMV growth to drive the profitability of the online pharmacy business.

### Consolidated - Quarterly Earning Model

Y/E March (INRm)	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Gross Sales</b>	<b>50,856</b>	<b>55,893</b>	<b>55,269</b>	<b>55,922</b>	<b>58,421</b>	<b>63,035</b>	<b>61,260</b>	<b>63,839</b>	<b>217,940</b>	<b>2,46,555</b>
YoY Change (%)	15.1	15.3	13.9	13.1	14.9	12.8	10.8	14.2	14.3	13.1
Total Expenditure	44,105	47,738	47,654	48,225	49,902	53,624	52,132	54,582	187,722	2,10,240
<b>EBITDA</b>	<b>6,751</b>	<b>8,155</b>	<b>7,615</b>	<b>7,697</b>	<b>8,519</b>	<b>9,411</b>	<b>9,128</b>	<b>9,257</b>	<b>30,218</b>	<b>36,314</b>
YoY Change (%)	32.6	30.0	24.1	20.2	26.2	15.4	19.9	20.3	26.4	20.2
Margins (%)	13.3	14.6	13.8	13.8	14.6	14.9	14.9	14.5	13.9	14.7
Depreciation	1,774	1,845	1,846	2,110	2,147	2,178	2,161	2,252	7,575	8,738
Interest	1,164	1,175	1,098	1,148	1,083	1,096	1,120	1,167	4,585	4,466
Other Income	372	382	638	611	402	547	560	758	2,003	2,267
<b>PBT</b>	<b>4,185</b>	<b>5,517</b>	<b>5,309</b>	<b>5,050</b>	<b>5,691</b>	<b>6,684</b>	<b>6,407</b>	<b>6,595</b>	<b>20,061</b>	<b>25,377</b>
Rate (%)	27.4	29.3	29.5	20.0	24.9	27.0	27.5	27.8	26.6	25.4
Minority Interest & Profit/Loss of Asso. Cos.	-12	112	18	144	-54	105	82	71	262	204
<b>Reported PAT</b>	<b>3,052</b>	<b>3,788</b>	<b>3,723</b>	<b>3,896</b>	<b>4,328</b>	<b>4,772</b>	<b>4,563</b>	<b>4,690</b>	<b>14,459</b>	<b>18,714</b>
<b>Adj PAT</b>	<b>3,052</b>	<b>3,788</b>	<b>3,723</b>	<b>3,896</b>	<b>4,328</b>	<b>4,772</b>	<b>4,563</b>	<b>4,690</b>	<b>14,459</b>	<b>18,800</b>
YoY Change (%)	83.2	63.5	51.8	53.5	41.8	26.0	22.6	20.4	61.1	30.0
Margins (%)	6.0	6.8	6.7	7.0	7.4	7.6	7.4	7.3	6.6	7.6



## Aurobindo Pharma

Buy

CMP: INR1,215 | TP: INR1,430 (18%)

EPS CHANGE (%): FY26|27|28: (0.8)|(0.8)|(0.7)

- Expect a 7% YoY decline in the US sales to USD405m during the quarter, partly due to reduced g-Revlimid
- Expect breakeven of China OSD facility; enhancing supply reliability and cost efficiency for European markets.
- Expect EU sales to grow 12.3% YoY to INR23b, driven by expanded offerings and increasing reach.
- Progress on capacity utilization of the PENG plant with govt in final stages to approve minimum import price for PEN-G.

### Consolidated - Quarterly Earning Model

(INRM)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	75,670	77,961	79,785	83,821	78,681	82,857	80,651	84,286	317,237	326,475
YoY Change (%)	10.5	8.0	8.5	10.6	4.0	6.3	1.1	0.6	9.4	2.9
Total Expenditure	58,724	62,299	63,507	65,202	62,647	66,076	63,714	64,479	249,732	256,916
EBITDA	16,947	15,661	16,278	18,619	16,034	16,781	16,937	19,807	67,505	69,559
YoY Change (%)	47.2	11.6	1.7	10.4	-5.4	7.1	4.0	6.4	15.5	3.0
Margins (%)	22.4	20.1	20.4	22.2	20.4	20.3	21.0	23.5	21.3	21.3
Depreciation	4,042	3,823	4,185	4,444	4,057	4,292	4,471	4,672	16,494	17,492
Interest	1,110	1,127	1,185	1,150	978	952	942	906	4,572	3,778
Other Income	1,199	1,360	1,573	1,232	1,053	1,156	1,380	1,400	5,364	4,989
Forex loss/(gain)	-10	0	498	-116	4	-50	0	0	372	-46
Exceptional (expenses)/income	249	0	0	(700)	0	0	0	0	-451	0
PBT	13,254	12,072	11,983	13,673	12,049	12,743	12,904	15,628	50,981	53,324
Tax	4,057	3,905	3,543	4,323	3,826	4,278	3,484	5,575	15,827	17,163
Rate (%)	30.6	32.3	29.6	31.6	31.8	33.6	27.0	35.7	31.0	32.2
Minority Interest	4	-7	-18	315	-25	-20	105	111	294	172
Reported PAT	9,193	8,174	8,458	9,035	8,248	8,485	9,315	9,942	34,860	35,989
Adj PAT	9,013	8,174	8,809	9,434	8,250	8,451	9,315	9,939	35,430	35,956
YoY Change (%)	51.9	5.1	-2.4	-6.6	-8.5	3.4	5.7	5.4	7.9	1.5
Margins (%)	11.9	10.5	11.0	11.3	10.5	10.2	11.5	11.8	11.2	11.0

## Biocon

Buy

CMP: INR393|TP: INR460 (17%)

EPS CHANGE (%): FY26|27|28: 0|0|0

- Expect biologics sales to grow 22% YoY to INR27.8b, supported by new launches and better traction in existing products
- Expect Syngene sales to grow 8% YoY to INR10.2b.
- Outlook on GLP1 filings in other emerging markets.
- Increased competition in the generics segment is expected to keep generics sales at INR8.1b.
- Expect scale-up in biologics sales from the launch of Insulin Aspart in the US.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	34,329	35,904	38,214	44,170	39,420	42,960	45,447	47,054	152,617	174,880
YoY Change (%)	0.3	3.7	6.0	12.8	14.8	19.7	18.9	6.5	5.9	14.6
Total Expenditure	28,120	29,040	30,357	33,390	31,770	34,610	36,494	37,596	120,907	140,470
EBITDA	6,209	6,864	7,857	10,780	7,650	8,350	8,953	9,458	31,710	34,411
YoY Change (%)	-12.9	-7.4	36.2	17.7	23.2	21.6	13.9	-12.3	7.6	8.5
Margins (%)	18.1	19.1	20.6	24.4	19.4	19.4	19.7	20.1	20.8	19.7
Depreciation	4,050	4,200	4,250	4,360	4,550	4,730	4,825	4,995	16,860	19,100
Interest	2,360	2,260	2,230	2,120	2,770	2,720	2,350	2,100	8,970	9,940
Other Income	767	330	350	370	800	930	960	980	1,817	3,670
Extraordinary Income	10,893	260	-163	210	-170	-120	0	0	11,200	-290
PBT	11,459	994	1,564	4,880	960	1,710	2,738	3,343	18,897	8,751
Tax Rate (%)	24.8	71.4	47.9	5.7	8.3	22.8	21.5	21.0	24.2	20.1
Minority Interest	2,030	430	560	1,150	580	480	570	590	4,170	2,220
PAT	6,589	-146	254	3,450	300	840	1,580	2,051	10,147	4,770
Adj PAT	-1,604	365	439	3,252	300	910	1,580	2,051	2,452	4,840
YoY Change (%)	-260.4	-74.7	-125.8	128.4	-118.7	149.2	259.6	-36.9	13.2	97.4
Margins (%)	19.2	-0.4	0.7	7.8	0.8	2.0	3.5	4.4	6.6	2.7

## Cipla

Neutral

CMP: INR1,511 | TP: INR1,500 (-1%)

EPS CHANGE (%): FY26|27|28: (0.8)|(0.3)|(0.5)

- US sales to decline 15% YoY to USD192m for 3QFY26, driven by higher competition in g-Revlimid.
- Expect DF sales to witness single-digit growth of 7% YoY, hurt by a decline in Gastro and muted growth in AI.
- Progress on the deal with Eli Lilly to distribute and promote Terzapatide in India.
- Expanding into the Orthopaedics to broaden therapy coverage in India, supported by product launches in recent quarter.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Revenues	66,939	70,510	70,730	67,297	69,575	75,894	72,820	70,259	275,476	288,548
YoY Change (%)	5.8	5.6	7.1	9.2	3.9	7.6	3.0	4.4	6.9	4.7
Total Expenditure	49,781	51,654	50,841	51,921	51,793	56,947	56,945	54,099	204,197	219,784
EBITDA	17,158	18,856	19,889	15,376	17,781	18,948	15,875	16,159	71,279	68,763
YoY Change (%)	14.9	8.8	13.8	16.9	3.6	0.5	-20.2	5.1	13.3	-3.5
Margins (%)	25.6	26.7	28.1	22.8	25.6	25.0	21.8	23.0	25.9	23.8
Depreciation	2,467	2,717	2,798	3,087	2,527	2,970	3,118	3,009	11,070	11,624
Interest	180	154	146	140	141	132	110	100	620	482
Other Income	1,602	1,906	1,546	2,895	2,586	2,690	2,300	2,400	7,949	9,975
Profit before Tax	16,114	17,891	18,491	15,043	17,699	18,535	14,946	15,451	67,538	66,632
One-time (expense)/income	0	0	670	0	0	0	0	0	670	0
Tax	4,351	4,830	3,324	2,793	4,779	5,005	3,737	3,940	15,298	17,460
Rate (%)	27.0	27.0	18.0	18.6	27.0	27.0	25.0	25.5	22.7	26.2
Minority Interest	-13.5	34.9	132.1	31.8	-55.7	19.0	-60.0	-140.0	185.3	-236.7
Reported PAT	11,776	13,025	15,705	12,218	12,976	13,512	11,270	11,651	52,725	49,409
Adj PAT	11,776	13,025	13,644	12,218	12,976	13,512	11,270	11,651	50,664	49,409
YoY Change (%)	18.3	10.9	14.0	40.6	10.2	3.7	-17.4	-4.6	19.6	-2.5

## Dr Agarwal's Healthcare

Buy

CMP: INR502 | TP: INR600 (20%)

EPS CHANGE (%): FY26|27|28: 0|0|0

- Expect sales growth of 20%, largely led by the number of patients being treated.
- Watch out for the performance of newly launched facilities opened in Hassan/Palakkad.
- Progress on addition of facilities in 3Q as well as in upcoming quarters.
- Progress on the merger of Dr. Agarwal's Eye Hospital with Dr. Agarwal's Healthcare.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	4,035	4,166	4,307	4,602	4,874	4,987	5,169	5,445	17,110	20,475
YoY Change (%)			29.5	31.9	20.8	19.7	20.0	18.3	28.4	19.7
Total Expenditure	2,998	3,096	3,211	3,272	3,596	3,626	3,830	4,059	12,578	15,111
EBITDA	1,037	1,070	1,096	1,330	1,279	1,361	1,339	1,386	4,532	5,364
YoY Change (%)			23.2	24.2	23.3	27.3	22.1	4.2	25.1	18.4
Margins (%)	25.7	25.7	25.4	28.9	26.2	27.3	25.9	25.4	26.5	26.2
Depreciation	555	572	582	604	630	679	690	705	2,313	2,703
Interest	270	284	284	250	247	226	230	270	1,088	972
Other Income	60	119	127	154	134	79	131	147	460	491
Extra-Ord expense	0	0	-52	45	0	0	0	0	7	0
PBT	272	333	409	585	536	537	550	558	1,599	2,180
Tax	89	119	128	160	155	172	162	144	495	632
Rate (%)	32.6	35.9	31.2	27.3	29.0	32.0	29.4	25.7	31.0	29.0
MI & P/L of Asso. Cos.	62	48	59	100	80	68	75	73	269	296
Reported PAT	121	165	223	326	301	297	313	342	835	1,252
Adj PAT	121	165	187	358	301	297	313	342	832	1,252
YoY Change (%)			-5.6	-7.4	148.3	79.5	67.3	-4.6	0.2	50.5
Margins (%)	3.0	4.0	4.3	7.8	6.2	6.0	6.1	6.3	4.9	6.1
EPS	0.4	0.5	0.6	1.1	1.0	0.9	1.0	1.1	2.7	4.0

## Divis Labs

Neutral

**CMP: INR6,390 | TP: INR6,930 (8%)**
**EPS CHANGE (%): FY26|27|28: (1.6)|(0.2)|(0.1)**

- DIVI is expected to deliver 15.5% YoY growth in sales on account of growth across segments.
- Expect 20%/5% YoY growth in CS/Generics sales for the quarter.
- Continue to add newer API molecules to sustain competitiveness while navigating weak pricing cycles.
- Progress on iodine-based/ gadolinium-based contrast media-related projects.

### Consolidated - Quarterly Earning Model

Y/E March (INRm)	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Net Sales</b>	<b>21,180</b>	<b>23,380</b>	<b>23,190</b>	<b>25,850</b>	<b>24,100</b>	<b>27,150</b>	<b>26,788</b>	<b>27,935</b>	<b>93,600</b>	<b>105,973</b>
YoY Change (%)	19.1	22.5	25.0	12.2	13.8	16.1	15.5	8.1	19.3	13.2
Total Expenditure	14,960	16,220	15,760	16,990	16,810	18,270	18,350	18,940	63,930	72,370
<b>EBITDA</b>	<b>6,220</b>	<b>7,160</b>	<b>7,430</b>	<b>8,860</b>	<b>7,290</b>	<b>8,880</b>	<b>8,438</b>	<b>8,995</b>	<b>29,670</b>	<b>33,603</b>
YoY Change (%)	23.4	43.5	51.9	21.2	17.2	24.0	13.6	1.5	33.5	13.3
Margins (%)	29.4	30.6	32.0	34.3	30.2	32.7	31.5	32.2	31.7	31.7
Depreciation	970	990	990	1,070	1,120	1,130	1,128	1,165	4,020	4,543
Interest	0	0	0	10	30	80	0	0	10	110
Other Income	780	770	720	760	800	820	833	795	3,030	3,249
<b>PBT before EO Income</b>	<b>6,030</b>	<b>6,940</b>	<b>7,160</b>	<b>8,540</b>	<b>6,940</b>	<b>8,490</b>	<b>8,143</b>	<b>8,625</b>	<b>28,670</b>	<b>32,199</b>
Forex gain/(Loss)	10	290	100	100	390	630	0	0	500	1,020
<b>PBT</b>	<b>6,040</b>	<b>7,230</b>	<b>7,260</b>	<b>8,640</b>	<b>7,330</b>	<b>9,120</b>	<b>8,143</b>	<b>8,625</b>	<b>29,170</b>	<b>33,219</b>
Tax	1,740	2,120	1,370	2,020	1,880	2,230	1,995	2,156	7,250	8,261
Rate (%)	28.8	29.3	18.9	23.4	25.6	24.5	24.5	25.0	24.9	24.9
<b>PAT</b>	<b>4,300</b>	<b>5,110</b>	<b>5,890</b>	<b>6,620</b>	<b>5,450</b>	<b>6,890</b>	<b>6,148</b>	<b>6,469</b>	<b>21,920</b>	<b>24,957</b>
<b>Adj. PAT</b>	<b>4,293</b>	<b>4,905</b>	<b>5,809</b>	<b>6,543</b>	<b>5,160</b>	<b>6,414</b>	<b>6,148</b>	<b>6,469</b>	<b>21,550</b>	<b>24,191</b>
YoY Change (%)	20.3	38.3	68.5	22.0	20.2	30.8	5.8	-1.1	35.3	12.3
Margins (%)	20.3	21.9	25.4	25.6	22.6	25.4	23.0	23.2	23.4	23.6
<b>Adj. EPS</b>	<b>16.2</b>	<b>18.5</b>	<b>21.9</b>	<b>24.7</b>	<b>19.4</b>	<b>24.2</b>	<b>23.2</b>	<b>24.4</b>	<b>81.2</b>	<b>91.1</b>

## Dr Reddy's Labs

Neutral

**CMP: INR1,255 | TP: INR1,249 (-1%)**
**EPS CHANGE (%): FY26|27|28: (4.7)|(0.1)|(0.1)**

- Expect NA sales to decline 21.6% YoY to USD310m, led by increased pricing pressure on g-Revlimid.
- Progress on semaglutide approval for the Canadian market. Progress on traction of differentiated products/categories in India market.
- Expect India business to grow 11% YoY, led by robust traction in the vaccine/cardiac/pain segment.
- Progress on filing Abatacept with the USFDA. Exploring a US CMO partnership to mitigate potential tariff related risks.

### Consolidated - Quarterly Earning Model (IFRS)

(INRm)

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Sales</b>	<b>76,727</b>	<b>80,162</b>	<b>82,320</b>	<b>85,060</b>	<b>85,452</b>	<b>88,051</b>	<b>80,851</b>	<b>84,714</b>	<b>324,269</b>	<b>339,068</b>
YoY Change (%)	13.9	16.5	14.1	20.1	11.4	9.8	-1.8	-0.4	16.2	4.6
Total Expenditure	55,452	58,134	60,590	64,555	63,951	66,798	63,630	63,959	238,731	258,338
<b>EBITDA</b>	<b>21,275</b>	<b>22,028</b>	<b>21,730</b>	<b>20,505</b>	<b>21,501</b>	<b>21,253</b>	<b>17,221</b>	<b>20,755</b>	<b>85,538</b>	<b>80,730</b>
YoY Change (%)	4.0	10.3	7.1	16.1	1.1	-3.5	-20.7	1.2	9.1	-5.6
Margins (%)	27.7	27.5	26.4	24.1	25.2	24.1	21.3	24.5	26.4	23.8
Amortization	3,815	3,975	4,719	4,555	4,765	5,051	4,400	4,820	17,064	19,036
Other Income	1,366	2,600	461	3,374	2,311	3,510	2,350	2,200	7,801	10,371
<b>PBT before EO expenses</b>	<b>18,826</b>	<b>20,653</b>	<b>17,472</b>	<b>19,324</b>	<b>19,047</b>	<b>19,712</b>	<b>15,171</b>	<b>18,135</b>	<b>76,275</b>	<b>72,065</b>
One-off income/(expense)	-5	-1,486	1,270	730	0	-1,362	0	0	509	-1,362
<b>Profit before Tax</b>	<b>18,821</b>	<b>19,167</b>	<b>18,742</b>	<b>20,054</b>	<b>19,047</b>	<b>18,350</b>	<b>15,171</b>	<b>18,135</b>	<b>76,784</b>	<b>70,703</b>
Rate (%)	26.0	30.0	25.1	20.8	26.0	22.2	25.0	25.5	25.4	24.7
Minority Interest	0	862	-95	-66	-82	-104	-95	-110	701	-391
<b>Reported Profit</b>	<b>13,920</b>	<b>12,553</b>	<b>14,133</b>	<b>15,939</b>	<b>14,178</b>	<b>14,372</b>	<b>11,473</b>	<b>13,621</b>	<b>56,545</b>	<b>53,644</b>
<b>Adjusted PAT</b>	<b>13,924</b>	<b>13,593</b>	<b>13,182</b>	<b>15,361</b>	<b>14,178</b>	<b>15,431</b>	<b>11,473</b>	<b>13,621</b>	<b>56,060</b>	<b>54,703</b>
YoY Change (%)	2.0	2.4	-4.3	26.7	1.8	13.5	-13.0	-11.3	6.1	-2.4
Margins (%)	18.1	17.0	16.0	18.1	16.6	17.5	14.2	16.1	17.3	16.1

## Eris Lifesciences

Neutral

CMP: INR1,531 | TP: INR1,530 (0%)

EPS CHANGE (%): FY26|27|28: 0.0|0.0|0.0

- Eris is expected to deliver 15% YoY growth in sales.
- DF growth is likely to be witness healthy growth, led by superior show in Cardiac/Derma
- Watch out ANVISA's approval for oral liquid line at AMD unit with oral solid and injectables inspection scheduled
- Watch out upside from RHI Cartridges opportunity.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Gross Sales	7,197	7,412	7,275	7,053	7,730	7,924	8,366	8,605	28,936	32,624
YoY Change (%)	54.2	46.7	49.6	28.0	7.4	6.9	15.0	22.0	44.0	12.7
Total Expenditure	4,697	4,767	4,771	4,529	4,963	5,042	5,321	5,473	18,764	20,798
EBITDA	2,500	2,645	2,503	2,524	2,767	2,882	3,045	3,132	10,172	11,826
Margins (%)	34.7	35.7	34.4	35.8	35.8	36.4	36.4	36.4	35.2	36.2
Depreciation	759	805	812	773	705	691	772	794	3,149	2,962
Interest	604	595	572	543	487	496	521	508	2,313	2,011
Other Income	16	46	42	80	27	28	33	34	184	123
PBT before EO expense	1,153	1,291	1,162	1,288	1,602	1,724	1,785	1,865	4,894	6,975
Extra-Ord expense	0	0	0	-1	-9	-3	0	0	-1	-12
PBT	1,153	1,291	1,162	1,289	1,611	1,727	1,785	1,865	4,895	6,987
Tax	259	328	292	265	360	382	407	431	1,144	1,580
Rate (%)	22.5	25.4	25.2	20.6	22.3	22.1	22.8	23.1	23.4	22.6
Minority Interest & Profit/Loss of Asso. Cos.	62	48	33	85	71	143	110	129	228	452
Reported PAT	832	916	836	938	1,180	1,202	1,268	1,305	3,522	4,955
Adj PAT	832	916	836	938	1,173	1,200	1,268	1,305	3,522	4,946
YoY Change (%)	-12.3	-25.8	-18.6	15.0	41.0	31.0	51.6	39.2	-12.4	40.4
Margins (%)	11.6	12.4	11.5	13.3	15.2	15.1	15.2	15.2	12.2	15.2

## GSK Pharma

Neutral

CMP: INR,2,483 | TP: INR2,560 (3%)

EPS CHANGE (%): FY26|27|28: 2.5|1.8|1.7

- Expect sales growth of 11% YoY for the quarter, led by scale-up of products launched in recent past and healthy traction in legacy brands.
- Outlook on the launch and scale-up of Oncology products in the DF segment is a key monitorable.
- Progress on building the adult immunization category with Shingrix via digital screening and ongoing clinic initiatives
- Watch out for pipeline from parent to be launched in India.

### Consolidated - Quarterly Earning Model

(INRM)

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4Q		
Net Sales	8,147	10,107	9,494	9,743	8,052	9,799	10,529	10,615	37,491	38,996
YoY Change (%)	7.0	5.6	17.9	4.8	-1.2	-3.0	10.9	8.9	8.6	4.0
Total Expenditure	5,841	6,891	6,665	6,412	5,541	6,442	6,886	6,857	25,809	25,727
EBITDA	2,305	3,216	2,829	3,332	2,511	3,357	3,643	3,758	11,682	13,269
YoY Change (%)	60.2	11.1	29.7	29.5	8.9	4.4	28.8	12.8	28.6	13.6
Margins (%)	28.3	31.8	29.8	34.2	31.2	34.3	34.6	35.4	31.2	34.0
Depreciation	164	169	188	147	155	174	197	203	668	728
Interest	4	3	1	6	4	5	2	1	13	12
Other Income	356	345	351	407	437	336	300	550	1,459	1,623
PBT before EO Expense	2,494	3,391	2,991	3,585	2,789	3,514	3,745	4,104	12,461	14,151
Tax	671	913	782	957	740	965	992	1,067	3,323	3,764
Rate (%)	26.9	26.9	26.2	26.7	26.5	27.5	26.5	26.0	26.7	26.6
Adjusted PAT	1,823	2,477	2,209	2,628	2,049	2,549	2,752	3,037	9,138	10,387
YoY Change (%)	58.6	13.9	5.7	36.8	12.4	2.9	24.6	15.6	24.6	13.7
Margins (%)	22.4	24.5	23.3	27.0	25.5	26.0	26.1	28.6	24.4	26.6
One-off Expense/(Income)	0	-47	-90	0	0	-26	0	0	-137	-26
Reported PAT	1,823	2,524	2,299	2,628	2,049	2,575	2,752	3,037	9,275	10,414
Reported PAT incl disc operations	1,823	2,477	2,209	2,628	2,049	2,575	2,752	3,037	9,138	10,414

## Gland Pharma

Buy

CMP: INR1,714 | TP: INR2,090 (22%)

EPS CHANGE (%): FY26|27|28: (2.6)|(0.6)|(0.9)

- Expect sales growth of 16% in 3QFY26, led by improvement in core market and Cenexi performance.
- Progress on increasing capacity utilization of GLP-1 pens/cartridge for non-regulated market.
- Watch out facility upgrade/modification and addition of lyophilizers line at Cenexi facility.
- Status of approval for limited competition products in pipeline for next 9-12M.

### Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	14,017	14,058	13,841	14,249	15,056	14,869	16,065	17,055	56,165	63,045
YoY Change (%)	16.0	2.4	-10.4	-7.3	7.4	5.8	16.1	19.7	-0.9	12.3
Total Expenditure	11,373	11,088	10,241	10,774	11,378	11,730	12,258	12,910	43,476	48,276
EBITDA	2,644	2,970	3,600	3,475	3,678	3,139	3,807	4,144	12,689	14,769
YoY Change (%)	-10.1	-8.3	-3.8	-3.1	39.1	5.7	5.8	19.3	-6.1	16.4
Margins (%)	18.9	21.1	26.0	24.4	24.4	21.1	23.7	24.3	22.6	23.4
Depreciation	920	938	963	958	1,011	1,063	1,009	1,072	3,779	4,155
Interest	56	61	228	75	115	78	68	59	420	320
Other Income	514	597	585	440	575	842	623	647	2,136	2,687
PBT before EO expense	2,182	2,567	2,993	2,883	3,128	2,839	3,353	3,661	10,626	12,981
One-off income/(expense)	0	0	0	0	0	0	0	0	0	0
PBT	2,182	2,567	2,993	2,883	3,128	2,839	3,353	3,661	10,626	12,981
Tax	745	932	946	1,018	973	1,002	1,006	1,073	3,641	4,054
Rate (%)	34.1	36.3	31.6	35.3	31.1	35.3	30.0	29.3	34.3	31.2
Reported PAT	1,438	1,635	2,047	1,865	2,155	1,837	2,347	2,588	6,985	8,928
Adj PAT	1,438	1,635	2,047	1,865	2,155	1,837	2,347	2,588	6,985	8,928
YoY Change (%)	-25.9	-15.8	0.4	-2.7	49.9	12.3	14.7	38.8	-10.9	27.8
Margins (%)	10.3	11.6	14.8	13.1	14.3	12.4	14.6	15.2	12.4	14.2
EPS	8.7	9.9	12.4	11.3	13.1	11.2	14.3	15.7	42.4	54.2

## Glenmark Pharma

Buy

CMP: INR2,066 | TP: INR2,380 (15%)

EPS CHANGE (%): FY26|27|28: (8.7)|4|0.3

- DF is expected to grow 8.5% YoY. The growth will be driven by healthy uptake in Tevimbra/Brukinsa/Jabra offset by discontinuation of low margin brands.
- Progress on scale-up of DF business post GST led inventory corrections.
- US sales expected to deliver 4.1% YoY, on price erosion in the base portfolio. EU sales expected to deliver 15% YoY growth supported by Ryaltris/Winlevi.
- Cardiac/respiratory/anti-infective to drive growth in 3Q based on IQVIA data for 3M ending Nov'25.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Revenues (Core)	32,442	34,338	33,876	32,562	32,644	23,769	37,704	38,320	133,217	132,437
YoY Change (%)	6.9	7.1	35.1	6.3	0.6	-30.8	11.3	17.7	12.8	-0.6
EBITDA	6,102	6,019	6,002	5,610	5,805	-8,704	8,483	9,005	23,734	14,589
YoY Change (%)	39.5	19.1	-515.5	11.2	-4.9	-244.6	41.3	60.5	82.2	-38.5
Margins (%)	18.8	17.5	17.7	17.2	17.8	-36.6	22.5	23.5	17.8	11.0
Depreciation	1,178	1,203	1,227	1,252	1,299	1,412	1,328	1,379	4,860	5,418
Interest	396	485	523	667	582	665	250	55	2,071	1,551
Other Income	315	324	311	117	264	2,006	135	140	1,067	2,546
One-off loss/(gain)	220	-70	0	3,728	3,232	-18,449	0	0	3,878	-15,217
PBT after EO Exp.	4,623	4,726	4,563	80	956	9,674	7,041	7,711	13,992	25,382
Rate (%)	26.4	25.0	23.7	45.0	50.9	36.9	25.0	25.5	25.2	30.7
Rep. PAT	3,402	3,545	3,480	44	470	6,104	5,281	5,745	10,471	17,600
Minority Interest	0	3	1	-3	1	1	0	-2	0	0
Rep. PAT after Minority Int.	3,403	3,542	3,480	47	469	6,104	5,281	5,747	10,471	17,600
Adj PAT	3,565	3,490	3,480	2,932	3,140	-8,776	5,281	5,747	13,466	5,392
YoY Change (%)	220.9	149.8	-199.8	74.6	-11.9	NA	51.8	96.0	1,821.0	-60.0
Margins (%)	11.0	10.2	10.3	9.0	9.6	-36.9	14.0	15.0	10.1	4.1
Overall Adj. PAT	3,565	3,490	3,480	2,932	3,140	(8,776)	5,281	5,747	13,466	5,392



## Global Health

Buy

CMP: INR1,217 | TP: INR1,480 (22%)

EPS CHANGE (%): FY26|27|28: 0|0|0

- ARPOB is expected to grow 11% YoY in mature hospitals, while developing hospitals may see modest 4% YoY growth.
- International patient volumes should remain strong and continue to support revenue growth.
- Occupancy at mature hospitals is expected to remain stable, while developing hospitals' occupancy is projected to rise
- Noida ramp-up is likely to pressure margins in the near term due to operating cost absorption but would start contributing meaningfully to revenue in the upcoming quarters.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Gross Sales	8,611	9,566	9,434	9,312	10,308	10,992	10,684	9,748	36,923	41,733
YoY Change (%)	11.4	13.3	12.8	15.2	19.7	14.9	13.2	4.7	12.7	13.0
Total Expenditure	6,699	7,222	7,023	7,066	8,038	8,683	8,291	7,350	28,008	32,362
EBITDA	1,912	2,344	2,412	2,247	2,270	2,309	2,393	2,398	8,915	9,371
YoY Change (%)	3.7	7.3	8.9	17.6	18.7	-1.5	-0.8	6.7	7.6	5.1
Margins (%)	22.2	24.5	25.6	24.1	22.0	21.0	22.4	24.6	24.1	22.5
Depreciation	515	555	519	493	451	497	559	510	2,082	2,017
Interest	180	160	163	150	138	171	160	165	653	634
Other Income	219	182	160	229	205	197	252	264	791	918
PBT before EO expense	1,437	1,811	1,891	1,833	1,886	1,838	1,926	1,987	6,972	7,637
Extra-Ord expense/(Income)	0	0	0	-499	196	160	0	0	-499	356
PBT	1,437	1,811	1,891	1,334	2,081	1,998	1,926	1,987	6,473	7,993
Tax	374	503	462	321	492	414	405	427	1,659	1,737
Rate (%)	26.0	27.8	24.4	24.0	23.6	20.7	21.0	21.5	25.6	21.7
Minority Interest & Asso. Cos. P/L	0	0	0	0	0	0	0	0	0	0
Reported PAT	1,063	1,308	1,429	1,014	1,590	1,584	1,522	1,560	4,813	6,255
Adj PAT	1,063	1,308	1,429	1,393	1,440	1,458	1,522	1,560	5,193	5,977
YoY Change (%)	4.2	4.5	15.6	9.4	35.6	11.4	6.5	12.0	8.6	15.1
Margins (%)	12.3	13.7	15.1	15.0	14.0	13.3	14.2	16.0	14.1	14.3

## Granules India

Buy

CMP: INR615 | TP: INR710 (15%)

EPS CHANGE (%): FY26|27|28: (3.3)|(0.4)|1.2

- Growth is expected to be driven by capacity expansion, portfolio diversification, and stronger compliance.
- Progress on CDMO scale-up as well as integration of the peptides R&D platform with India manufacturing.
- Progress on re-inspection at Gagillapur facility.
- USFDA approval for GLS's Hyderabad facility in Nov'25 should further contribute the finished-dosage business.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	11,799	9,666	11,377	11,974	12,101	12,970	12,611	13,920	44,816	51,602
YoY Change (%)	19.7	-18.7	-1.5	1.8	2.6	34.2	10.9	16.2	-0.5	15.1
Total Expenditure	9,206	7,633	9,074	9,451	9,634	10,188	9,837	10,788	35,364	40,446
EBITDA	2,593	2,033	2,303	2,524	2,467	2,782	2,775	3,132	9,452	11,156
YoY Change (%)	64.2	-4.5	-8.1	-1.3	-4.8	36.8	20.5	24.1	7.8	18.0
Margins (%)	22.0	21.0	20.2	21.1	20.4	21.5	22.0	22.5	21.1	21.6
Depreciation	529	525	566	635	688	720	715	737	2,255	2,861
EBIT	2,064	1,508	1,737	1,889	1,779	2,062	2,060	2,395	7,197	8,295
YoY Change (%)	90.0	-6.0	-12.3	-6.7	-13.8	36.7	18.6	26.8	7.5	15.3
Margins (%)	17.5	15.6	15.3	15.8	14.7	15.9	16.3	17.2	16.1	16.1
Interest	270	257	266	240	238	292	283	283	1,032	1,096
Other Income	21	32	57	19	163	-11	32	35	129	218
PBT before EO expense	1,814	1,284	1,528	1,668	1,704	1,759	1,808	2,147	6,294	7,418
Extra-Ord expense	0	0	0	-308	259	0	0	0	-308	259
PBT	1,814	1,284	1,528	1,976	1,445	1,759	1,808	2,147	6,601	7,159
Tax	468	311	352	455	319	453	405	487	1,587	1,664
Rate (%)	25.8	24.3	23.0	23.0	22.1	25.7	22.4	22.7	24.0	23.2
Minority Interest & Asso. Cos. P/L	0	0	0	0	0	0	0	0	0	0
Reported PAT	1,346	972	1,176	1,520	1,126	1,306	1,403	1,659	5,015	5,495
Adjusted PAT	1,346	972	1,176	1,284	1,328	1,306	1,403	1,659	4,778	5,697
YoY Change (%)	112.7	-4.8	-6.4	-1.0	-1.4	34.3	19.3	29.3	13.6	19.2
Margins (%)	11.4	10.1	10.3	10.7	11.0	10.1	11.1	11.9	10.7	11.0



## Ipca Laboratories

Buy

CMP: INR1,404 | TP: INR1,645 (17%)

EPS CHANGE (%): FY26|27|28: (1.1)|(1.1)|(1.1)

- Overall sales are expected to grow 7.2% YoY, driven by domestic growth across Formulations and APIs.
- Weakness in Unichem performance to affect overall YoY growth for the quarter.
- DF is expected to grow 12.5% YoY, led by strong execution in antineoplastics, pain, and cardiac therapies, partially offset by stable growth in anti-infectives.
- Growth across both chronic and acute therapies should continue to support DF performance.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Revenues (Core)	20,926	23,549	22,454	22,467	23,089	25,565	24,081	23,804	89,396	96,538
YoY Change (%)	31.8	15.8	9.4	10.5	10.3	8.6	7.2	5.9	16.0	8.0
EBITDA	3,927	4,425	4,631	4,289	4,164	5,449	4,840	4,427	17,271	18,881
YoY Change (%)	33.5	22.7	39.9	33.2	6.0	23.2	4.5	3.2	32.1	9.3
Margins (%)	18.8	18.8	20.6	19.1	18.0	21.3	20.1	18.6	19.3	19.6
Depreciation	989	1,004	985	1,001	1,001	1,033	1,026	1,014	3,978	4,073
EBIT	2,938	3,421	3,646	3,287	3,164	4,416	3,815	3,414	13,293	14,808
YoY Change (%)	30.7	26.6	57.5	46.9	7.7	29.1	4.6	3.8	39.9	11.4
Margins (%)	14.0	14.5	16.2	14.6	13.7	17.3	15.8	14.3	14.9	15.3
Interest	241	226	168	215	185	196	184	171	849	736
Other Income	206	263	201	258	327	279	290	310	928	1,205
PBT before EO Expense	2,904	3,458	3,679	3,331	3,305	4,498	3,921	3,553	13,372	15,277
One-off (gain)/ Expense	0	0	0	2,051	0	583	0	0	2,051	583
PBT after EO Expense	2,904	3,458	3,679	1,280	3,305	3,916	3,921	3,553	11,321	14,694
Tax	914	994	906	622	961	1,081	1,161	1,066	3,436	4,268
Rate (%)	31.5	28.7	24.6	48.6	29.1	27.6	29.6	30.0	25.7	27.9
Reported PAT	1,990	2,464	2,773	658	2,344	2,835	2,760	2,487	7,885	10,426
Minority Interest & Asso. Cos. P/L	-67	-160	-292	20	-12	-9	19	20	-499	18
Adj PAT after Minority Int	1,922	2,305	2,481	2,418	2,332	3,247	2,779	2,507	9,127	10,866
YoY Change (%)	24.9	36.4	122.5	23.4	21.3	40.9	12.0	3.7	44.8	19.1
Margins (%)	9.2	9.8	11.1	10.8	10.1	12.7	11.5	10.5	10.2	11.3

## Laurus Labs

Buy

CMP: INR1,107 | TP: INR1,280 (16%)

EPS CHANGE (%): FY26|27|28: 0.0|0.0|0.0

- Expect 17.4% YoY growth in revenue with quarterly run-rate crossing previous highs.
- EBITDA margins are projected to expand by 420 bps versus 3QFY25, driven by an improved CDMO mix and cost optimization initiatives.
- The FDF and API businesses are expected to sustain momentum, delivering ~15% YoY growth in 3Q.
- Phase I of the Vizag fermentation facility is expected to become operational by 4QFY26, providing an additional growth driver for the bio business.

### Consolidated- Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	11,949	12,237	14,151	17,203	15,696	16,535	16,611	17,968	55,540	66,809
YoY Change (%)	1.1	-0.1	18.4	19.5	31.4	35.1	17.4	4.4	10.2	20.3
EBITDA	1,712	1,783	2,852	4,206	3,821	4,033	3,887	4,600	10,553	16,340
YoY Change (%)	2.7	-5.1	57.2	74.2	123.2	126.1	36.3	9.4	35.7	54.8
Margins (%)	14.3	14.6	20.2	24.4	24.3	24.4	23.4	25.6	19.0	24.5
Depreciation	1,061	1,075	1,061	1,104	1,168	1,205	1,232	1,306	4,301	4,911
EBIT	651	708	1,791	3,102	2,653	2,828	2,655	3,293	6,252	11,429
YoY Change (%)	-14.5	-25.1	115.7	122.8	307.3	299.3	48.3	6.2	59.1	82.8
Margins (%)	5.5	5.8	12.7	18.0	16.9	17.1	16.0	18.3	11.3	17.1
Interest	492	526	578	564	515	400	443	459	2,160	1,817
Other Income	25	46	94	-3	104	270	56	52	163	482
PBT before EO expense	185	228	1,307	2,535	2,242	2,697	2,268	2,887	4,254	10,095
PBT	185	228	1,307	3,123	2,242	2,697	2,268	2,887	4,843	10,095
Tax	63	51	401	785	631	760	635	794	1,299	2,820
Rate (%)	33.9	22.3	30.7	25.1	28.2	28.2	28.0	27.5	26.8	27.9
Minority Interest & Asso. Cos. P/L	-5	-21	-17	20	7	-3	15	16	13	36
Reported PAT	127	198	923	2,319	1,603	1,940	1,618	2,077	3,531	7,239
Adj PAT	127	198	923	1,878	1,603	1,940	1,618	2,077	3,126	7,239
YoY Change (%)	-52.7	-46.3	298.9	148.4	1,164.5	877.9	75.3	10.6	92.4	131.5
Margins (%)	1.1	1.6	6.5	10.9	10.2	11.7	9.7	11.6	5.6	10.8

## Laxmi Dental

Buy

CMP: INR271 | TP: INR340 (26%)

EPS CHANGE (%): FY26|27|28: (10.7)|(3.8)|(3.7)

- Revenue is expected to grow at a low double-digit rate, impacted by global policy-related headwinds and a temporary slowdown in the Bizdent business.
- EBITDA margins are expected to remain broadly stable, due to lower operating leverage.
- Change in geo-political scenario will be a key monitorable.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	597	571	617	607	656	723	678	784	2,391	2,841
YoY Change (%)	N/A	N/A	29.0	10.2	9.9	26.5	10.0	29.2	23.5	18.8
Total Expenditure	457	484	520	511	537	612	573	613	1,972	2,335
EBITDA	140	87	96	95	119	110	105	171	419	506
YoY Change (%)	N/A	N/A	144.7	-18.5	-15.0	26.3	9.4	79.8	76.1	20.8
Margins (%)	23.5	15.3	15.6	15.7	18.2	15.3	15.5	21.8	17.5	17.8
Depreciation	34	34	40	43	36	37	39	44	150	156
EBIT	106	53	57	52	83	73	66	127	269	349
YoY Change (%)	N/A	N/A	728.8	-38.0	-21.7	36.6	16.8	143.1	126.7	30.0
Interest	14	12	15	13	5	2	2	1	54	10
Other Income	4	7	6	16	17	24	22	15	33	78
PBT before EO expense	96	49	47	56	96	94	86	141	248	417
Extra-Ord expense	-59	0	0	-4	0	0	0	0	-70	0
PBT	155	49	47	60	96	94	86	141	318	417
Tax	18	11	11	25	23	19	20	24	65	86
Rate (%)	11.4	23.3	22.7	41.2	23.8	19.8	23.5	17.2	20.3	20.6
MI & P/L of Asso. Cos.	-20	-22	-12	-8	10	10	10	53	64	83
Reported PAT	157	59	48	43	83	85	75	170	318	414
Adj PAT	105	59	48	40	83	85	75	170	262	414
YoY Change (%)	N/A	N/A	133.2	-51.0	-21.3	44.8	57.1	319.5	4.9	58.3
Margins (%)	17.6	10.3	7.8	6.7	12.6	11.8	11.1	21.6	10.9	14.6

## Lupin

Neutral

CMP: INR2,106 | TP: INR2,125 (1%)

EPS CHANGE (%): FY26|27|28: 1.5|1.2|1.2

- US growth is expected to remain strong, supported by Tolvaptan exclusivity and continued traction in Mirabegron and g-Spiriva, offsetting mild price erosion.
- Increased focus on chronic therapies should result in relatively better growth for domestic formulations in 3Q, majorly driven by cardiac/respiratory therapies.
- Emerging markets, including Brazil and South Africa, are expected to drive growth.
- EBITDA margins may moderate sequentially due to higher R&D spend and lower PLI income.

### Consolidated- Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	56,003	55,427	56,927	56,671	62,684	70,475	67,614	62,860	2,25,028	2,63,632
YoY Change (%)	21.5	10.0	9.5	14.2	11.9	27.1	18.8	10.9	13.6	17.2
Total Expenditure	42,389	43,059	43,162	43,750	46,269	49,099	48,614	46,265	1,72,361	1,90,247
EBITDA	13,614	12,368	13,765	12,921	16,415	21,376	18,999	16,595	52,668	73,386
YoY Change (%)	109.0	34.0	34.7	29.6	20.6	72.8	38.0	28.4	46.6	39.3
Margins (%)	24.3	22.3	24.2	22.8	26.2	30.3	28.1	26.4	23.4	27.8
Depreciation	2,477	2,569	2,715	3,932	2,990	3,168	3,434	3,192	11,693	12,783
EBIT	11,137	9,799	11,050	8,989	13,425	18,208	15,566	13,403	40,975	60,603
YoY Change (%)	167.3	45.1	44.5	21.3	20.5	85.8	40.9	49.1	57.7	47.9
Margins (%)	19.9	17.7	19.4	15.9	21.4	25.8	23.0	21.3	18.2	23.0
Interest	680	709	669	891	918	1,076	820	554	2,949	3,367
Other Income	678	423	537	570	790	900	620	140	2,207	2,450
EO Exp/(Inc)	1,204	-1,036	956	-291	-859	-2,037	0	0	834	-2,896
PBT	9,930	10,549	9,963	8,958	14,156	20,070	15,366	12,989	39,401	62,582
Tax	1,875	1,954	2,124	1,135	1,941	5,221	3,304	2,884	7,087	13,349
Rate (%)	18.9	18.5	21.3	12.7	13.7	26.0	21.5	22.2	18.0	21.3
Minority Interest & Asso. Cos. P/L	-42	-69	-37	-99	-24	-69	-70	-72	-246	-235
Reported PAT	8,013	8,526	7,802	7,726	12,191	14,779	11,992	10,034	32,067	48,996
Adj PAT	8,990	7,682	8,554	7,472	11,450	13,272	11,992	10,034	32,698	46,748
YoY Change (%)	214.9	55.5	42.6	47.0	27.4	72.8	40.2	34.3	73.2	43.0
Margins (%)	16.1	13.9	15.0	13.2	18.3	18.8	17.7	16.0	14.5	17.7

## Mankind Pharma

Buy

CMP: INR2,203 | TP: INR2,625 (19%)

EPS CHANGE (%): FY26|27|28: (0.3)|(3.5)|(2.4)

- Full quarter impact of BSV and gradual revival in DF sales is expect to drive 11.6% YoY growth in sales.
- Expect OTC business to show growth uptick post GST led disruption in earlier quarter.
- Progress on results post corrective measures taken in Rx segment.
- Secondary sales for Mankind are expected to remain in the single digits, based on IQVIA data for the 3M ending Nov'25.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
(INR m)	1Q	2Q	3Q	4Q	1QE	2Q	3QE	4QE		
Gross Sales	28,934	30,765	31,988	30,794	35,704	36,972	35,711	33,982	1,22,481	1,42,369
YoY Change (%)	12.2	13.6	22.7	26.1	23.4	20.2	11.6	10.4	18.5	16.2
Total Expenditure	21,697	22,265	23,828	23,712	27,236	27,758	26,784	25,894	91,698	1,07,672
EBITDA	7,238	8,500	8,160	7,082	8,468	9,213	8,928	8,088	30,783	34,696
YoY growth %	10.5	24.5	34.5	19.8	17.0	8.4	9.4	14.2	21.4	12.7
Margins (%)	25.0	27.6	25.5	23.0	23.7	24.9	25.0	23.8	25.1	24.4
Depreciation	1,077	1,056	1,872	2,309	2,187	2,218	2,197	2,299	6,212	8,901
Interest	109	71	2,209	1,905	1,707	1,697	1,447	1,240	4,294	6,090
Other Income	1,006	1,094	770	1,013	799	919	839	856	5,368	3,412
PBT before EO expense	7,057	8,468	4,849	3,881	5,373	6,217	6,124	5,404	25,645	23,118
Extra-Ord expense	420	0	0	-1,250	0	0	0	0	-830	0
PBT	6,637	8,468	4,849	5,131	5,373	6,217	6,124	5,404	26,475	23,118
Tax	1,246	1,904	1,105	864	958	1,038	1,053	962	5,097	4,012
Rate (%)	18.8	22.5	22.8	16.8	17.8	16.7	17.2	17.8	19.3	17.4
Minority Interest & Asso. Cos. P/L	26.7	28.4	8.5	15.6	94.7	109.9	30.0	46.6	79.2	281.2
Reported PAT	5,365	6,535	3,736	4,251	4,320	5,069	5,040	4,396	21,298	18,825
Adj PAT	5,706	6,535	3,736	3,212	4,320	5,069	5,040	4,396	20,635	18,825
YoY Change (%)	17.2	30.4	-17.7	-31.8	-24.3	-22.4	34.9	36.9	7.9	-8.8
Margins (%)	19.7	21.2	11.7	10.4	12.1	13.7	14.1	12.9	16.8	13.2

## Max Healthcare

Buy

CMP: INR1,063 | TP: INR1,345 (27%)

EPS CHANGE (%): FY26|27|28: (6.7)|(1.3)|(1.4)

- ARPOB is expected to remain stable at INR 77.4k, impacted by the addition of institutional and insurance patients.
- Sales growth in 3Q is expected to be in the low single digits at ~4% YoY, impacted by GST-related issues as well as seasonality and normalization of JP related higher base of past year.
- 25% YoY growth in test volumes and 10% YoY improvement in realizations to drive a 37% YoY growth in Maxlab revenue.
- Insurance cashless disruptions is expected to impact 3Q performance.
- Maxhome is expected to deliver consistent 20% YoY growth

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Gross Sales	19,310	21,190	22,690	23,020	24,510	25,720	23,658	26,462	86,210	1,00,350
YoY Change (%)	19.1	23.3	34.9	28.5	26.9	21.4	4.3	15.0	26.5	16.4
Total Expenditure	14,370	15,520	16,520	16,950	18,340	18,850	17,365	19,396	63,360	73,952
EBITDA	4,940	5,670	6,170	6,070	6,170	6,870	6,293	7,065	22,850	26,398
Margins (%)	25.6	26.8	27.2	26.4	25.2	26.7	26.6	26.7	26.5	26.3
Depreciation	900	970	1,060	1,140	1,170	1,220	1,141	1,276	4,070	4,807
Interest	80	50	350	360	340	410	427	443	840	1,620
Other Income	40	60	110	240	80	80	120	130	450	410
PBT before EO expense	4,000	4,710	4,870	4,810	4,740	5,320	4,845	5,477	18,390	20,382
Extra-Ord expense	190	270	1,000	180	330	180	0	0	1,640	510
PBT	3,810	4,440	3,870	4,630	4,410	5,140	4,845	5,477	16,750	19,872
Tax	870	950	710	870	960	-410	896	1,024	3,400	2,470
Rate (%)	22.8	21.4	18.3	18.8	21.8	-8.0	18.5	18.7	20.3	12.4
Minority Interest & Asso. Cos. P/L	0	0	0	0	0	0	0	0	0	0
Reported PAT	2,940	3,490	3,160	3,760	3,450	5,550	3,949	4,453	13,350	17,401
Adj PAT	3,087	3,702	3,977	3,906	3,708	4,254	3,949	4,453	14,672	16,364
YoY Change (%)	1.0	4.9	16.5	17.7	20.1	14.9	-0.7	14.0	10.2	11.5
Margins (%)	16.0	17.5	17.5	17.0	15.1	16.5	16.7	16.8	17.0	16.3

## Piramal Pharma

Buy

CMP: INR179 | TP: INR210 (18%)

EPS CHANGE (%): FY26|27|28: (NA)|(12.5)|(8.7)

- Expect sales to increase 4% YoY to INR 22.9b, driven by YoY growth across all three segments: CDMO, CHG, and ICP.
- CHG sales are expected to grow 5% YoY following two stable quarters, supported by improved visibility on the resolution of supply-chain issues.
- EBITDA margins are expected to improve in 3Q, supported by better operating leverage.
- Scale-up of the CDMO business following the passage of the Biosecure Act will be a key monitorable.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Revenues	19,511	22,418	22,042	27,541	19,337	20,437	22,961	27,921	91,511	90,656
growth YoY(%)	11.6	17.3	12.5	7.9	-0.9	-8.8	4.2	1.4	12.0	-0.9
CDMO	10,570	13,240	12,780	17,880	9,970	10,440	13,036	17,344	54,470	50,789
CHG	6,310	6,430	6,540	7,050	6,370	6,440	6,867	7,508	26,330	27,185
ICH	2,640	2,770	2,780	2,740	3,020	3,190	3,058	3,069	10,930	12,337
EBITDA*	2,044	3,416	3,377	5,610	1,067	1,587	3,008	4,579	14,447	10,241
margin (%)	10.5	15.2	15.3	20.4	5.5	7.8	13.1	16.4	15.8	11.3
growth YoY(%)	54.5	28.6	25.8	5.9	-47.8	-53.5	-10.9	-18.4	20.8	-29.1
Depreciation	1,846	1,922	1,968	2,428	1,973	2,028	2,089	2,100	8,163	8,190
EBIT	198	1,494	1,409	3,182	-906	-441	919	2,479	6,284	2,051
Other income	195	611	121	420	584	656	555	590	1,348	2,385
Interest expense	1,070	1,076	1,033	1,037	862	824	860	855	4,216	3,401
Minority Interest & Asso. Cos. P/L	224	173	171	162	186	148	195	210	729	739
PBT	-452	1,201	668	2,728	-998	-462	809	2,424	4,145	1,773
Taxes	436	975	631	1,193	27	530	493	1,430	3,235	2,481
Tax Rate (%)	-96.4	81.2	94.5	43.7	-3.4	-114.9	61.0	59.0	78.0	125.2
Reported PAT	-888	226	37	1,535	-817	-992	315	994	910	-500
Adj. PAT	-888	226	37	1,535	-1,031	-992	315	994	910	-714
Change (%)	NA	348.2	-89.5	34.0	NA	NA	757.2	-35.3	62.5	-178.5

## Rubicon Research

Buy

CMP: INR662 | TP: INR780 (18%)

EPS CHANGE (%): FY26|27|28: 0|0|0

- Revenue is expected to grow 11% QoQ, supported by the scale-up of recently launched products and the commercialization of already approved assets.
- Expect quarterly revenue to cross previous highs.
- We expect gross margin to be on slight down trend due to higher outsourcing. R&D spend to remains elevated at 11% of sales to build potential product pipeline.
- Progress on traction in nasal spray products and branded products for US market.

### Consolidated - Quarterly Earning Model

Y/E March	FY25		FY26				FY25	FY26
INRm	1Q	2Q	1Q	2Q	3QE	4QE		
Gross Sales	3,167	2,960	3,525	4,120	4,580	5,045	12,843	17,270
YoY Change (%)	NA	NA	11.3	39.2	NA	NA	50.4	34.5
Total Expenditure	2,565	2,343	2,734	3,177	3,572	4,022	10,200	13,505
EBITDA	602	617	791	943	1,008	1,023	2,643	3,765
YoY Change (%)			31.4	52.9	NA	NA		
Margins (%)	19.0	20.8	22.4	22.9	22.0	20.3	20.6	21.8
Depreciation	94	81	96	119	135	146	366	495
EBIT	509	535	695	824	873	877	2,277	3,270
YoY Change (%)			36.7	54.0	NA	NA	NA	NA
Margins (%)	16.1	18.1	19.7	20.0	19.1	17.4	18	19
Interest	101	70	106	114	10	3	368	234
Other Income	4	27	6	7	8	13	36	35
PBT before EO expense	412	492	596	717	871	887	1,945	3,070
Extra-Ord expense	0	0	0	0	0	0	0	0
PBT	412	492	596	717	871	887	1,945	3,070
Tax	156	147	163	179	244	244	602	829
Rate (%)	37.9	29.9	27.3	24.9	28.0	27.5	30.9	27.0
Minority Interest & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0
Reported PAT	256	345	433	539	627	643	1,344	2,241
Adj PAT	256	345	433	539	627	643	1,344	2,241
YoY Change (%)	NA	NA	69.4	56.2	NA	NA	47.6	66.8
Margins (%)	8.1	11.6	12.3	13.1	13.7	12.7	10.5	13.0

## Sun Pharma

Buy

CMP: INR1,729 | TP: INR1,990 (15%)

EPS CHANGE (%): FY26|27|28: 0|0|0

- Growth of 12% YoY in 3Q is expected, driven by strong performance in domestic and emerging markets, along with incremental growth in the US market.
- Unloxcyt is expected to be launched in 3Q, providing additional support to growth in the US market.
- Expect to sustain outperformance versus the industry, with DF sales growing 13% YoY during the quarter, led by new product launches, including Ilumya.
- EM/RoW are expected to deliver healthy growth of 18%/14% YoY, driven by the addition of branded generics/innovative products.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Sales	1,25,245	1,32,642	1,30,569	1,28,156	1,37,861	1,44,052	1,46,486	1,46,256	5,16,612	5,74,655
YoY Change (%)	6.3	10.5	7.4	8.5	10.1	8.6	12.2	14.1	8.2	11.2
EBITDA	35,298	37,837	35,738	32,816	40,073	40,235	39,991	39,343	1,41,689	1,59,641
Margins (%)	28.2	28.5	27.4	25.6	29.1	27.9	27.3	26.9	27.4	27.8
Depreciation	6,551	6,259	6,306	6,638	7,006	7,295	6,703	6,692	25,754	27,695
EBIT	28,747	31,578	29,433	26,178	33,067	32,940	33,288	32,651	1,15,936	1,31,946
Interest	615	692	515	491	748	999	439	439	2,314	2,624
Other Income	6,608	3,811	7,041	7,561	5,298	5,430	7,487	7,765	25,022	25,980
PBT before EO expense	34,740	34,697	35,959	33,248	37,617	37,371	40,337	39,977	1,38,644	1,55,303
Extra-Ord expense	505	-1,281	1,195	705	5,890	-4,305	0	0	1,123	1,585
PBT	34,235	35,978	34,764	32,543	31,728	41,676	40,337	39,977	1,37,520	1,53,718
Tax	5,523	5,672	5,589	10,937	8,702	10,305	10,084	9,794	27,720	38,885
Rate (%)	16.1	15.8	16.1	33.6	27.4	24.7	25.0	24.5	20.2	25.3
Minority Interest & Asso. Cos. P/L	356	-95	142	108	240	191	130	133	511	694
Reported PAT	28,356	30,401	29,034	21,498	22,786	31,180	30,122	30,050	1,09,289	1,14,138
Adj PAT	27,494	29,052	27,637	28,891	29,961	27,939	30,123	30,050	1,13,075	1,18,073
YoY Change (%)	20.4	20.8	11.6	3.0	9.0	-3.8	3.7	8.7	13.4	4.4
Margins (%)	22.0	21.9	21.2	22.5	21.7	19.4	20.6	20.5	21.9	20.5

## Torrent Pharmaceuticals

Neutral

CMP: INR3,885 | TP: INR3,930 (1%)

EPS CHANGE (%): FY26|27|28: (0.6)|(0.8)|(0.9)

- DF is expected to sustain healthy YoY growth of ~10%, driven by continued focus on chronic therapies, field-force expansion, and the addition of new therapy areas.
- Progress on completion of JB chemical acquisition process. Progress on preparations for launching potential molecules like Semaglutide.
- US sales are expected to deliver healthy YoY growth of ~22.5%, supported by improved offtake under existing contracts and additional product launches.
- Brazil business is expected to maintain steady growth in the coming quarter, supported by a strong product portfolio and brand identity.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Net Revenues	28,590	28,890	28,090	29,590	31,780	33,020	31,944	32,659	1,15,160	1,29,404
YoY Change (%)	10.3	8.6	2.8	7.8	11.2	14.3	13.7	10.4	7.3	12.4
EBITDA	9,240	9,390	9,140	9,810	10,470	10,830	10,318	10,647	37,580	42,265
YoY Change (%)	16.8	13.8	5.2	11.1	13.3	15.3	12.9	8.5	11.6	12.5
Margins (%)	32.3	32.5	32.5	33.2	32.9	32.8	32.3	32.6	32.6	32.7
EBIT	7,270	7,410	7,150	7,800	8,460	8,790	8,232	8,514	29,630	33,996
YoY Change (%)	21.2	18.8	9.0	14.7	16.4	18.6	15.1	9.2	15.7	14.7
Margins (%)	25.4	25.6	25.5	26.4	26.6	26.6	25.8	26.1	25.7	26.3
Interest	750	640	570	560	560	480	520	510	2,520	2,070
Other Income	240	-160	330	-180	-370	-270	182	171	230	-287
PBT before EO Expense	6,760	6,610	6,910	7,060	7,530	8,040	7,894	8,175	27,340	31,639
One-off expenses	200	0	0	410	150	130	0	0	610	280
PBT after EO Expense	6,560	6,610	6,910	6,650	7,380	7,910	7,894	8,175	26,730	31,359
Tax	1,990	2,080	1,880	1,670	1,900	2,000	2,029	2,134	7,620	8,062
Rate (%)	29.4	31.5	27.2	23.7	25.2	24.9	25.7	26.1	27.9	25.5
Reported PAT	4,570	4,530	5,030	4,980	5,480	5,910	5,865	6,041	19,110	23,296
Adj PAT	4,709	4,530	5,030	5,287	5,591	6,007	5,865	6,041	19,556	23,505
YoY Change (%)	24.6	17.4	31.9	17.8	18.7	32.6	16.6	14.3	22.7	20.2
Margins (%)	16.5	15.7	17.9	17.9	17.6	18.2	18.4	18.5	17.0	18.2



## Zydu Lifesciences

**Neutral**

**CMP: INR915 | TP: INR975 (6%)**

**EPS CHANGE (%): FY26|27|28: (0.6)|0.4|0.6**

- Expect revenue to grow 20.9% YoY, driven by healthy performance in base business and full quarter impact of acquisitions
- US to deliver low single-digit growth of ~5.9% YoY, supported by new product launches.
- DF growth of ~11% YoY is expected, primarily driven by chronic therapies, including cardiac and respiratory therapies.
- Expansion of the Comfort Click franchise into additional markets will be a key monitorable.

### Consolidated - Quarterly Earning Model

Y/E March	FY25				FY26E				FY25	FY26E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Net Revenues</b>	<b>62,075</b>	<b>52,370</b>	<b>52,691</b>	<b>65,279</b>	<b>65,737</b>	<b>61,232</b>	<b>63,704</b>	<b>70,367</b>	<b>2,32,415</b>	<b>2,61,041</b>
YoY Change (%)	20.8	19.9	17.0	18.0	5.9	16.9	20.9	7.8	18.9	12.3
Total Expenditure	40,983	38,210	39,691	43,630	45,423	45,215	47,906	52,705	1,62,514	1,91,249
<b>EBITDA</b>	<b>21,092</b>	<b>14,160</b>	<b>13,000</b>	<b>21,649</b>	<b>20,314</b>	<b>16,017</b>	<b>15,799</b>	<b>17,662</b>	<b>69,901</b>	<b>69,792</b>
YoY Change (%)	37.6	33.1	20.2	33.2	-3.7	13.1	21.5	-18.4	31.8	-0.2
Margins (%)	34.0	27.0	24.7	33.2	30.9	26.2	24.8	25.1	30.1	26.7
<b>EBIT</b>	<b>18,939</b>	<b>11,824</b>	<b>10,710</b>	<b>19,270</b>	<b>17,933</b>	<b>12,998</b>	<b>12,668</b>	<b>14,271</b>	<b>60,743</b>	<b>57,871</b>
YoY Change (%)	40.0	34.4	20.7	35.7	-5.3	9.9	18.3	-25.9	33.8	-4.7
Margins (%)	30.5	22.6	20.3	29.5	27.3	21.2	19.9	20.3	26.1	22.2
Interest	322	251	320	766	847	1,013	830	790	1,659	3,480
Other Income	632	682	575	806	1,549	1,090	1,440	1,480	2,695	5,559
<b>PBT before EO Income</b>	<b>19,249</b>	<b>12,255</b>	<b>10,965</b>	<b>19,310</b>	<b>18,635</b>	<b>13,075</b>	<b>13,278</b>	<b>14,961</b>	<b>61,779</b>	<b>59,950</b>
EO Exp/(Inc)	252	-454	-876	2,590	-571	-4,141	0	0	1,512	-4,712
<b>PBT after EO Income</b>	<b>18,997</b>	<b>12,709</b>	<b>11,841</b>	<b>16,720</b>	<b>19,206</b>	<b>17,216</b>	<b>13,278</b>	<b>14,961</b>	<b>60,267</b>	<b>64,662</b>
Tax	4,361	3,731	1,795	4,232	4,340	4,540	3,253	3,695	14,119	15,829
Rate (%)	23.0	29.4	15.2	25.3	22.6	26.4	24.5	24.7	23.4	24.5
Minority Interest & Asso. Cos. P/L	-437	131	192	-779	-198	252	-350	-400	-893	-696
<b>Reported PAT</b>	<b>14,199</b>	<b>9,109</b>	<b>10,238</b>	<b>11,709</b>	<b>14,668</b>	<b>12,928</b>	<b>9,675</b>	<b>10,866</b>	<b>45,255</b>	<b>48,137</b>
<b>Adj PAT</b>	<b>14,393</b>	<b>8,788</b>	<b>9,495</b>	<b>13,643</b>	<b>14,226</b>	<b>10,150</b>	<b>9,675</b>	<b>10,866</b>	<b>46,320</b>	<b>44,917</b>
YoY Change (%)	28.2	19.1	26.3	16.1	-1.2	15.5	1.9	-20.4	22.3	-3.0
Margins (%)	23.2	16.8	18.0	20.9	21.6	16.6	15.2	15.4	19.9	17.2

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.